Article Sidebar
Published:
May 11, 2023DOI:
10.4314/tjpr.v22i4.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
lncRNA ENST00000434223 exerts regulatory effects on NSCLC cells via Wnt/β-catenin signaling pathway
Abstract
Purpose: To identify the role and underlying mechanism of lncRNA ENST00000434223 (lncRNA ENST) in the occurrence of NSCLC.
Methods: Quantitative real time-polymerase chain reaction (qRT-PCR) was used to evaluate relative lncRNA ENST, β-catenin, Wnt1, and cyclin D1 expression levels in NSCLC tissues, cells, and sera. Proliferation of NSCLC cells was assessed using CCK-8 assay, while Transwell assay was utilized in evaluating changes in cell invasion/migration. Changes in Wnt1, cyclin D1, and β-catenin expressions were determined using qRT-PCR, while alterations in their protein expressions were determined by western blot (WB). In vivo experiments were conducted in nude mice to investigate the effects of lncRNA ENST on tumor growth.
Results: lncRNA ENST expression was low in sera, cells, and tissues of NSCLC (p <0.05). Tumor metastasis and size, lymphatic metastasis, and clinical stage were correlated with lncRNA ENST expression (p < 0.05). It was found that ENST could be applied as independent prognostic factor in NSCLC patients. Upregulated expression of lncRNA ENST restrained cell migration, proliferation, and invasion (p < 0.05). Compared with t NC group, lncRNA ENST expression decreased expressions of Wnt1, cyclin D1, and β-catenin in SPC-A1 cells and A549 cells (p < 0.05).
Conclusion: lncRNA ENST inhibits the proliferation and apoptosis of NSCLC cells via Wnt/β-catenin pathway. Thus, it is a possible biomarker for NSCLC, and provides a novel insight into the clinical management of NSCLC.
